- Home
- FTDR vs AXSM Comparison
FTDR vs AXSM Comparison
Compare FTDR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- AXSM
- Stock Information
- Founded
- FTDR 1971
- AXSM 2012
- Country
- FTDR United States
- AXSM United States
- Employees
- FTDR N/A
- AXSM N/A
- Industry
- FTDR Diversified Commercial Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- AXSM Health Care
- Exchange
- FTDR Nasdaq
- AXSM Nasdaq
- Market Cap
- FTDR 4.4B
- AXSM 5.1B
- IPO Year
- FTDR 2018
- AXSM 2015
- Fundamental
- Price
- FTDR $65.60
- AXSM $116.78
- Analyst Decision
- FTDR Hold
- AXSM Strong Buy
- Analyst Count
- FTDR 4
- AXSM 17
- Target Price
- FTDR $59.75
- AXSM $175.76
- AVG Volume (30 Days)
- FTDR 636.0K
- AXSM 591.0K
- Earning Date
- FTDR 11-03-2025
- AXSM 11-11-2025
- Dividend Yield
- FTDR N/A
- AXSM N/A
- EPS Growth
- FTDR 29.61
- AXSM N/A
- EPS
- FTDR 3.36
- AXSM N/A
- Revenue
- FTDR $1,966,000,000.00
- AXSM $495,033,000.00
- Revenue This Year
- FTDR $14.54
- AXSM $64.05
- Revenue Next Year
- FTDR $6.49
- AXSM $56.46
- P/E Ratio
- FTDR $19.73
- AXSM N/A
- Revenue Growth
- FTDR 8.62
- AXSM 69.83
- 52 Week Low
- FTDR $35.61
- AXSM $75.56
- 52 Week High
- FTDR $67.26
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- FTDR 62.76
- AXSM 47.95
- Support Level
- FTDR $63.31
- AXSM $123.54
- Resistance Level
- FTDR $67.26
- AXSM $130.00
- Average True Range (ATR)
- FTDR 2.03
- AXSM 3.66
- MACD
- FTDR 0.39
- AXSM -0.95
- Stochastic Oscillator
- FTDR 79.68
- AXSM 4.51
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.